S&P 500 eases slightly from fresh record high after stronger economic growth
Marc D. Beer, a director at biote Corp. (NASDAQ:BTMD), a $147 million market cap company, recently increased his stake in the company by purchasing 107,794 shares of Class A Common Stock. InvestingPro analysis shows management has been actively buying back shares, signaling confidence despite the stock’s 34% decline year-to-date. The shares were acquired at a weighted average price of $3.87 per share, resulting in a total transaction value of $417,162. This purchase, executed on March 17, 2025, was carried out through multiple transactions with prices ranging from $3.55 to $4.00 per share. Following this transaction, Beer now directly owns 107,794 shares in the company. According to InvestingPro, which offers comprehensive analysis including 8 additional key insights for BTMD, the stock currently trades at a relatively high P/E ratio of 42x, with analysts projecting improved profitability this year.
In other recent news, Biote Corp reported its fourth-quarter 2024 earnings, with both earnings per share (EPS) and revenue missing analyst forecasts. The company posted an EPS of $0.10, slightly below the expected $0.11, and revenue of $49.8 million, which fell short of the projected $51.29 million. Following these results, Jefferies and Truist Securities adjusted their price targets for Biote, lowering them to $6.80 and $7.00, respectively, while maintaining a Buy rating on the stock. Analysts from both firms highlighted challenges related to the implementation of new software, which affected the growth of new practitioners, a key driver for Biote’s business model.
Despite these hurdles, Biote’s Board of Directors and CEO Bret Christensen demonstrated confidence in the company’s strategy by purchasing approximately 260,000 shares of the company’s common stock. The company also launched the BioTRx wellness platform and expanded its manufacturing capabilities, aiming to drive future growth. Looking ahead, Biote has set its 2025 revenue guidance between $200 million and $280 million. Additionally, the company expects procedure revenue to grow by 2-4% and dietary supplement revenue by 5-10% in 2025. These developments reflect Biote’s ongoing efforts to navigate current challenges and focus on long-term growth strategies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.